SecBot SecBot
144 ·Filed Nov 12, 2026

MIRM

Mirum Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4d 16h ago SEC0001950047-26-011005
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The sale is small and routine for a director. No material impact expected. Monitor for any pattern of larger insider sales or changes in insider sentiment in future filings.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$93.33
T+0 close · Nov 12, 2026 · via day close
Latest settled
+0.71%
T+1 · $93.99
Vs SPY
+1.07%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $93.33entry
  2. T+1 · 4d ago +0.71%α +1.07% · $93.99
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Laura Brege filed a Form 144 to sell 14,167 shares of Mirum Pharmaceuticals, valued at approximately $1.33 million, following a stock option exercise. The sale was executed on November 11, 2026, and the filing was delayed one day due to the Veterans Day federal holiday. The sale is small relative to the company's $6.2B market cap and represents a routine insider transaction.

Key Facts

  • Director Laura Brege filed Form 144 to sell 14,167 shares of common stock.
  • Sale value approximately $1,334,673.07 based on the filing.
  • Shares were acquired via stock option exercise on November 11, 2026.
  • Sale executed on November 11, 2026; filing delayed to November 12 due to federal holiday.
  • Broker: Morgan Stanley Smith Barney LLC Executive Financial Services.

Financial Impact

Sale of 14,167 shares valued at ~$1.33M, representing ~0.02% of the company's $6.2B market cap.

dilution

Risk Factors

  • Insider sale is small relative to market cap; no significant risk.
  • No other insider sales or unusual activity indicated in recent 30 days.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-011005
Document: 0001950047-26-011005-index.html0001950047-26-011005
Document: 0001950047-26-011005.txt0001950047-26-011005

Track record

27 reports on MIRM

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +28.29% at T+20 after the Jun 11, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $92.28 Now $91.58 −0.76% settles Feb 12
  2. Nov 13, 20263d ago Insider Cluster Neutral 3/10 Entry $93.54 Now $91.58 −2.10% settles Feb 12
  3. Nov 12, 20264d ago 144 Neutral 2/10 Viewing Entry $93.33 Now $91.58 −1.88% settles Feb 10
  4. Nov 10, 20266d ago 8-K Bullish 6/10 Entry $94.42 Now $91.58 −3.01% settles Feb 8
  5. Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
  6. Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
  7. Nov 3, 202613d ago 8-K Bullish 6/10 Entry $96.97 Now $91.58 −5.56% settles Feb 2
  8. Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $85.81 Now $91.58 +6.72% settles Jan 26
  9. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $85.56 Now $91.58 +7.04% settles Jan 25
  10. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $79.62 Now $91.58 +15.02% settles Jan 8
Showing 10 of 27

US Market Status

Market Closed · Opens in 8h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026